Miltefosine

Andrew Stewardson, Douglas Johnson

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

1 Citation (Scopus)

Abstract

Miltefosine (hexadecylphosphocholine) is an alkylphosphocholine (APC) lipid analog. It was initially developed as an oral antineoplastic agent but was abandoned owing to dose-limiting gastrointestinal toxicity. It was subsequently found to have useful activity at tolerable dosages against a range of microorganisms, including protozoa and fungi. Clinically, its activity against Leishmania species has received the most attention, as it represented the first effective oral agent for that group of organisms. It was first registered for the treatment of (visceral) leishmaniasis in 2002.

Original languageEnglish
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
EditorsM. Lindsay Grayson
Place of PublicationBoca Raton FL USA
PublisherCRC Press
Pages3292-3309
Number of pages18
Edition7th
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
Publication statusPublished - 2 Oct 2017
Externally publishedYes

Cite this

Stewardson, A., & Johnson, D. (2017). Miltefosine. In M. L. Grayson (Ed.), Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (7th ed., pp. 3292-3309). CRC Press.